| Literature DB >> 16419285 |
Abstract
The Food and Drug Administration's approval in June 2005 of a heart failure drug aimed at black patients marks the first time that the agency has approved a drug for a specific racial group. When added to standard heart failure therapy, BiDil dramatically reduces death and hospitalization in blacks.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16419285
Source DB: PubMed Journal: FDA Consum ISSN： 0362-1332